天美传媒

Abstract

A number of second-line metastatic breast cancer trials have been conducted comparing the progestational agent, megesterol acetate, and a third-generation aromatase inhibitor following failure. At a minimum, these selective aromatase inhibitors demonstrated equivalent if not superior efficacy to megesterol acetate in patients with resistant advanced metastatic breast cancer as a second-line therapy, thus paving the way for direct head-to-head comparisons with th established first-line hormonal agent.

Keywords: Efficacy; Hormone; Treatment; Inhibitor; Stabilization; Progression